Blood Cancers Today Executive Editor Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center discusses the latest news and novel therapies in chronic lymphocytic leukemia (CLL).
Related Posts
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
AMPLIFY trial shows AVO combo achieves deep remissions in CLL patients with high-risk TP53 aberrations.
10-year RESONATE-2 results show ibrutinib delivers lasting survival benefits for CLL/SLL as first-line therapy.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.